George Lemaitre Sells 55,930 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 55,930 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer directly owned 1,476,500 shares in the company, valued at $159,181,465. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

LeMaitre Vascular Price Performance

LMAT stock opened at $107.85 on Wednesday. The firm has a 50 day simple moving average of $87.95 and a two-hundred day simple moving average of $88.48. The stock has a market cap of $2.46 billion, a PE ratio of 42.97, a P/E/G ratio of 2.01 and a beta of 0.66. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $115.33. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm’s revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be given a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date is Thursday, March 12th. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is currently 31.87%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LMAT shares. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wells Fargo & Company upped their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Citizens Jmp upped their price target on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $105.80.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently added to or reduced their stakes in LMAT. Parkside Financial Bank & Trust increased its position in shares of LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 287 shares during the period. Cornerstone Planning Group LLC grew its stake in shares of LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 283 shares during the last quarter. MAI Capital Management purchased a new position in LeMaitre Vascular during the 3rd quarter valued at about $38,000. First Horizon Corp bought a new position in LeMaitre Vascular during the 3rd quarter valued at approximately $39,000. Finally, Geneos Wealth Management Inc. lifted its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Company announced a dividend increase (quarterly dividend raised to $0.25) and a share buyback program, a catalyst that lifted investor sentiment and helped drive the rally. Read More.
• Positive Sentiment: Analyst support has improved — at least one firm raised its price target to $118 and other shop upgrades/positive notes add buy-side conviction around the stock. Read More.
• Positive Sentiment: Technical picture is constructive after a recent “golden cross” (50‑day MA crossing above 200‑day), which can attract momentum and technical buying. Read More.
• Neutral Sentiment: Recent quarterly results beat consensus (EPS and revenue) and management set FY2026 guidance (EPS 2.81–3.01), which provides useful context for longer-term holders but is already baked into current momentum. Read More.
• Negative Sentiment: Significant insider selling was reported recently — including CEO George W. LeMaitre (150,000 shares on Feb 26 and 55,930 on Mar 2), a director sale and an officer sale — totaling roughly ~215k shares disclosed across filings; this could create short‑term selling pressure or raise governance/insider‑confidence questions for some investors. Read More.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.